Shalby Ltd (SHALBY) Q3FY26 Concall Summary - Dec-2025 Qtr
Performance Overview
- The company reported a marginal decline in consolidated revenue and EBITDA for the quarter, primarily attributed to a temporary halt in business with major insurance companies due to rate negotiations, which have since been resolved.
- The hospital business faced challenges from the departure of key doctors in two units and management issues at the Shalby International (PK Healthcare) facility, impacting occupancy rates.
- Despite challenges, the company has made significant investments in technology, including five orthopedic robots and two for other specialties, and has upgraded infrastructure with new radiation oncology bunkers to drive future growth.
- The Medtech (implant) business demonstrated a significant turnaround, achieving positive consolidated EBITDA and strong year-on-year revenue growth of 29%, driven by robust performance in the Indian and Southeast Asian markets.
- Management expressed a positive outlook, expecting a double-digit volume growth in the hospital segment in the upcoming year, supported by the resolution of insurance tie-ups, new doctor hirings (40 added vs. 18 lost), and the operationalization of recent technological investments.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.